Scott Requadt

Biography

 Scott Requadt, JD, MBA, is currently a Managing Director at Clarus, a life sciences investment firm. Scott has over 15 years of operating and investment experience in the pharmaceutical industry. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals (acquired by J&J), and previously practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance) from McGill University (First Class Honors), an LL.B from University of Toronto, and an MBA from Harvard Business School (Baker Scholar). Mr. Requadt has been involved in multiple Clarus investments spanning both therapeutics and medtech, including Intercept Pharmaceuticals (Nasdaq: ICPT) as well as several R&D risk-sharing collaborations with large pharma partners. Scott currently serves on the Boards of ESSA Pharmaceuticals (Nasdaq: EPIX), AvroBio, and Edev. He has previously been active on the Boards of TyRx (acquired by Medtronic), Catabasis (Nasdaq: CATB), Oxford Immunotec (Nasdaq: OXFD), Link Medicine (acquired by AstraZeneca), and Biolex Therapeutics.

Research Interest

 life sciences